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Background: Paclitaxel, a widely-used antineoplastic drug, produces a painful peripheral neuropathy that in rodents is
associated with peripheral-nerve mitochondrial alterations. The sigma-1 receptor (σ1R) is a ligand-regulated molecular
chaperone involved in mitochondrial calcium homeostasis and pain hypersensitivity. This receptor plays a key role in
paclitaxel-induced neuropathic pain, but it is not known whether it also modulates mitochondrial abnormalities.
In this study, we used a mouse model of paclitaxel-induced neuropathic pain to test the involvement of the σ1R in the
mitochondrial abnormalities associated with paclitaxel, by using genetic (σ1R knockout mice) and pharmacological
(σ1R antagonist) approaches.
Results: Paclitaxel administration to wild-type (WT) mice produced cold- and mechanical-allodynia, and an increase in
the frequency of swollen and vacuolated mitochondria in myelinated A-fibers, but not in C-fibers, of the saphenous
nerve. Behavioral and mitochondrial alterations were marked at 10 days after paclitaxel-administration and had resolved
at day 28. In contrast, paclitaxel treatment did not induce allodynia or mitochondrial abnormalities in σ1R knockout
mice. Moreover, the prophylactic treatment of WT mice with BD-1063 also prevented the neuropathic pain and
mitochondrial abnormalities induced by paclitaxel.
Conclusions: These results suggest that activation of the σ1R is necessary for development of the sensory nerve
mitochondrial damage and neuropathic pain produced by paclitaxel. Therefore, σ1R antagonists might have
therapeutic value for the prevention of paclitaxel-induced neuropathy.
Keywords: Paclitaxel, Sigma-1 receptors, Chemotherapy-induced peripheral neuropathy, BD-1063, Mitochondria,
Allodynia, Neuropathic pain, Sigma-1 receptor knockout miceBackground
Paclitaxel is a first-line antitumor agent that frequently pro-
duces neuropathic pain, for which no treatment is available
[1,2]. However, experimental models of paclitaxel-induced
neuropathy are allowing the testing of novel treatments
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unless otherwise stated.e.g., [3-6]. Emerging evidence suggests that paclitaxel-
induced neuropathy is a consequence of toxic effects
on mitochondria. In particular, an increased incidence
of swollen and vacuolated axonal mitochondria in
peripheral sensory fibers appears to be relevant [7,8].
This increase in atypical mitochondria has been at-
tributed to the binding of paclitaxel to mitochondrial
β-tubulin, which may produce Ca2+ release from mi-
tochondria and dysregulated intracellular Ca2+ home-
ostasis [7,9]. In fact, paclitaxel-induced neuropathic
pain in rodents is prevented and/or reversed by
agents that either enhance mitochondrial functiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of mitochondrial function and/or intracellular Ca2+ levels
may also contribute to other peripheral neuropathies [13].
The sigma-1 receptor (σ1R) has been identified as
a ligand-regulated molecular chaperone [14] and pro-
posed as a modulator of several receptors and ion
channels [15]. Specifically, at mitochondrion-associated
endoplasmic reticulum membrane (MAM) level, the
σ1R chaperone modulates the intramitochondrial Ca
2+
level and plays a key role in the control of intracellular
Ca2+ homeostasis [16]. σ1Rs are highly expressed in the
central and peripheral nervous system, including import-
ant areas for pain control [17-19], and the involvement
of σ1R in pain modulation is well documented [20-26].
Accordingly, σ1Rs have been proposed as an emerging tar-
get for the treatment of neuropathic pain [27]. Our group
recently reported that paclitaxel-induced pain is reduced
in σ1 receptor knockout (σ1R-KO) mice and in wild-type
(WT) mice treated with σ1R antagonists [28]. However, it
is not known whether the beneficial effects of σ1R block-
ade on paclitaxel-induced neuropathic pain are associated
with a reduction of the mitochondrial abnormalities in-
duced by the antineoplastic.
In this study, we first compared the paclitaxel-induced
changes in hind-paw pain perception (acetone and elec-
tronic Von Frey tests) and in saphenous nerve mitochon-
drial characteristics (transmission electron microscopy
analysis) in WT mice. We then evaluated whether σ1R in-
hibition by treatment with a selective σ1R antagonist (BD-
1063) or genetic inactivation (σ1R-KO mice) prevents the
neuropathic pain behaviors and mitochondrial changes in-
duced by paclitaxel. The present report shows that pacli-
taxel treatment induces pain behaviors in parallel with the
occurrence of mitochondrial abnormalities in WT mice,
and that pharmacologically- or genetically-induced σ1R
blockade prevents both types of abnormality.
Results
Behavioral pain studies
On the pretreatment day, WT and σ1R-KO mice showed
a similar duration of acetone-induced paw licking/biting
(Figure 1a) and a similar threshold force for paw with-
drawal in the electronic Von Frey test (Figure 1b). Treat-
ment with paclitaxel vehicle did not significantly modify
the response of WT or σ1R-KO mice in any test at any
measurement time point (Figure 1a and b). However,
on day 10 after the first paclitaxel injection, WT mice
showed a statistically significant increase in acetone-
induced paw licking/biting duration (cold-allodynia) and
a reduction in threshold force for paw withdrawal in the
electronic Von Frey test (mechanical allodynia) (Figure 1a
and b). On day 28 after the first paclitaxel dose, the re-
sponse of WT animals had returned to normal values in
both tests (Figure 1a and b). In contrast, the paclitaxel-treated σ1R-KO mice showed no sign of cold or mechan-
ical allodynia at any time point (Figure 1a and b). Likewise,
the s.c prophylactic administration of the selective σ1R
antagonist BD-1063 (32 mg/kg) to WT animals, totally
prevented the development of cold and mechanical allody-
nia (Figure 1c and d). Therefore, σ1R inhibition induced
by genetic inactivation (σ1R-KO mice) or treatment with a
selective σ1R antagonist (BD-1063) completely averted the
neuropathic pain behavioral manifestations induced by
paclitaxel administration.
All treated animals were in good general health at the
end of the treatment and all gained weight normally
(data not shown).
Electron microscopy analysis of saphenous nerve in
control WT and σ1R-KO mice
Figure 2 illustrates the ultrastructural characteristics of
myelinated and unmyelinated fibers in WT control mice.
Normal axoplasmic structures (neurotubules and neuro-
filaments) can be identified in both myelinated and un-
myelinated fibers (Figure 2). Mitochondria within fibers
are typically characterized as circular or oval structures
containing cristae and amorphous electron dense ma-
terial enveloped by double membranes (Figure 2e). The
ultrastructural characteristics of myelinated and unmy-
elinated fibers in σ1R-KO control mice were similar to
those of WT control mice. Hence, the results show an
absence of significant histological differences between
the different types of fibers in both groups of animals.
Morphometric measurement of the mitochondrial area
showed an ample range of values (< 0.03 to > 0.42 μm2)
in the two types of saphenous nerve fiber, with a similar
distribution pattern in WT and σ1R-KO control mice
(Figure 3a and b). In fact, the mean areas of the mito-
chondria of each fiber type were virtually identical in
both WT and σ1R-KO control mice (Table 1). However,
in both groups of mice, the mean mitochondrial areas
were significantly larger in unmyelinated C-fibers than
in myelinated A-fibers (Table 1).
Electron microscopy analysis of saphenous nerve fibers in
paclitaxel-treated WT and σ1R-KO mice
Ultrastructural study of saphenous nerves from paclitaxel-
treated WT and σ1R-KO mice showed no evidence of
axonal, Schwann cell, or myelin degeneration, or of aggre-
gates of neurotubules. However, mitochondrial alterations
were observed in axons of saphenous nerves, especially in
WT mice, at day 10 from the start of paclitaxel treatment.
These alterations were associated with an enlarged size
(swelling) and vacuolization of mitochondria (Figure 4),
resulting in a statistically significant increase in mean mito-
chondrial area of 31% in A-fibers (from 0.102 to 0.134 μm2)
of WT animals (Table 1). In contrast, paclitaxel-treatment
only slightly (7%) and non-significantly increased the mean
Figure 1 Effects of σ1R blockade in paclitaxel-induced neuropathic pain behaviors. Effect of paclitaxel + saline and paclitaxel-vehicle + saline
on the duration of hind paw licking/biting in the acetone test (a) and on the threshold force for hind paw withdrawal in the electronic Von Frey
test (b) in WT and σ1R-KO mice. Time-courses of the effect of paclitaxel + saline, paclitaxel + BD-1063 (32 mg/kg), and paclitaxel-vehicle + saline in
the acetone test (c) and in the electronic Von Frey test (d) in WT mice. The animals were treated once daily from days 1 to 5 with an i.p. injection
of paclitaxel (2 mg/kg) or its vehicle (a,b) and with an s.c. injection of BD-1063 or saline 30 min before each paclitaxel dose (c,d). The response
was recorded in each animal 3 days before (PRE) and on days 10 and 28 after the start of treatment. Each point and vertical line represents the
mean ± SEM of the values obtained in 6–12 animals. Statistically significant differences between WT mice treated with paclitaxel + saline and the
rest of the groups on the same day after treatment, **p < 0.01; and between the values on the pretreatment day and the days after treatment,
## p < 0.01 (two-way repeated measures ANOVA followed by Bonferroni test).
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0.115 μm2) (Table 1). Paclitaxel also increased the mean
mitochondrial area in unmyelinated fibers of WT and
σ1R-KO mice, but this effect did not reach statistically
significance in any genotype and was of similar magni-
tude than that produced by paclitaxel-vehicle (Table 1).
Because previous studies [7,8] reported an increase inatypical mitochondria in paclitaxel-treated animals, we
analyzed in detail the population of atypical mitochon-
dria in the experimental groups.
Figure 5 depicts the percentage of atypical mitochondria
in the A- and C-fibers of WT and σ1R-KO mice before
any treatment and at 10 and 28 days after the first dose of
paclitaxel or its vehicle. Treatment with the paclitaxel-
Figure 2 Transmission electron micrographs of myelinated and unmyelinated fibers of the saphenous nerve from WT mice. Cross-section of
myelinated and unmyelinated fibers (a); cross-section of unmyelinated fibers with Schwann cell nucleus (b); high magnification of myelinated
(c) and unmyelinated (d) fibers; representative photograph of a normal axonal mitochondrion (e). Scale bar: 1 μm (a-d) and 0.5 μm (e).
Figure 3 Mitochondrial area distribution in fibers of saphenous nerve from WT and σ1R-KO mice. Mitochondrial area distribution in
myelinated (a) and unmyelinated (b) fibers of saphenous nerve from control WT and σ1R-KO mice. Morphometric analysis of the mitochondrial
area showed a wide range of values (<0.03 to > 0.42 μm2) in both types of nerve fiber. Each point represents the percentage of mitochondria in a
particular size range. Note the absence of differences between the mitochondrial area of WT and σ1R-KO animals in either fiber type.
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Table 1 Comparison of mitochondrial area in myelinated
and unmyelinated fibers of saphenous nerves obtained
from naive wild type (WT) and σ1-receptor knockout
(σ1R-KO) mice and from animals of both genotypes
10 days after treatment with paclitaxel or its vehicle
Mean mitocondrial area (μm2)
Genotype Treatment Myelinated Unmyelinated
WT Naive 0.102 ± 0.002 0.135 ± 0.016#
Vehicle 0.117 ± 0.008 0.164 ± 0.006##
Paclitaxel 0.134 ± 0.007** 0.161 ± 0.009#
σ1R-KO Naive 0.107 ± 0.005 0.134 ± 0.010
#
Vehicle 0.116 ± 0.005 0.164 ± 0.021##
Paclitaxel 0.115 ± 0.006 0.170 ± 0.007##
Values represent the mean mitochondrial area of the results obtained in 3–5
animals per experimental group. Statistically significant differences in
comparison to naive WT animals: **P < 0.01 (one way ANOVA followed by
Bonferroni test). Note that paclitaxel did not significantly enhance the mean
mitochondrial area in σ1R-KO mice myelinated fibers, nor in any genotype in
unmyelinated fibers. Statistically significant differences in comparison to
myelinated fiber: #P < 0.05; ##P < 0.01 (two way ANOVA followed by Bonferroni
test). Note that mitochondrial area was greater in unmyelinated than
myelinated fibers in all the experimental groups.
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the percentage of atypical mitochondria in either fiber
type in either WT or σ1R-KO mice (Figure 5a and b).
However, at 10 days after the first administration of
paclitaxel, a statistically significant and substantial in-
crease in the percentage of atypical mitochondria was
observed in the myelinated fibers of WT mice (from
2.20 ± 0.69% in pretreatment group to 15.53 ± 2.00% at
day 10 posttreatment, a posttreatment:pretreatment ratio
of 7.06) (Figure 5a). In contrast, the percentage of atypical
mitochondria in the A-fibers of σ1R-KO mice showed a
small and non-significant increase after 10 days of pacli-
taxel treatment (posttreatment/pretreatment ratio = 2.07)
(Figure 5a). At day 10, paclitaxel-treated WT mice showed
statistically significant differences with vehicle-treated WT
mice and with both paclitaxel- and vehicle-treated σ1R-
KO mice (Figure 5a). Analysis of the incidence of atypical
mitochondria in C-fibers at 10 days of paclitaxel treatment
revealed only small and non-significant increases in the
percentage of atypical mitochondria in WT (posttreat-
ment/pretreatment ratio = 1.45) and σ1R-KO (posttreat-
ment/pretreatment ratio = 1.89) mice (Figure 5b).
At 28 days of paclitaxel treatment, no statistically
significant changes were observed in the percentage of
atypical mitochondria in myelinated or unmyelinated
fibers in either WT or σ1R-KO mice (Figure 5a and b).
At this day, the ultrastructural characteristics of mye-
linated and unmyelinated fibers and their mitochon-
dria were undistinguishable from that observed in
naive animals in both WT and σ1R-KO mice (Figure 6a
and b).Electron microscopy analysis of saphenous nerve
mitochondria in WT mice treated with paclitaxel and the
σ1R antagonist BD-1063
Administration of BD-1063 (32 mg/kg, s.c.) before each
paclitaxel dose completely prevented the paclitaxel-
induced increase in the percentage of atypical mito-
chondria in myelinated fibers of WT mice at day 10
(Figure 7a). At day 28, the ultrastructural characteris-
tics of saphenous nerve fibres (Figure 6c) and the per-
centage of atypical mitochondria in myelinated nerve
fibers (Figure 7a) in BD-1063-treated animals were
similar to those observed before paclitaxel treatment.
Administration of BD-1063 did not produce any statis-
tically significant effect on the percentage of atypical
mitochondria in C-fibers (Figure 7b).
Discussion
The main finding of this study is that the pharmaco-
logical blockade or genetic knockout of σ1R prevents the
increased incidence of atypical axonal mitochondria in
saphenous nerve myelinated fibers and the neuropathic
pain signs associated with the administration of pacli-
taxel in mice. These findings suggest, for the first time,
an involvement of the σ1R in the paclitaxel-evoked mito-
chondrial abnormalities that appear to be important in
the pathophysiology of paclitaxel-induced neuropathy.
We confirm here that paclitaxel induces cold and
mechanical allodynia in WT mice as previously reported
[5,28,29]. However, when activation of σ1R was hindered,
through a genetic or pharmacologic approach, the devel-
opment of paclitaxel-induced allodynia was completely
prevented, suggesting a key role for the σ1R in this type
of neuropathic pain. These results are in agreement with
those of previous studies demonstrating that σ1R-KO
mice [23,24,30] and WT animals pretreated with σ1R
antagonists [20-22,28,31] showed a marked reduction of
pain in different models that activate central sensi-
tization mechanisms. In addition, it has been reported
that the spinal σ1R system contributes to diabetic neuro-
pathic pain in mice [25]. Therefore, the present and pre-
viously published behavioral data strongly support the
involvement of σ1R in modulating pain, especially neuro-
pathic pain.
Our paclitaxel treatment schedule induced an increase
in the frequency of atypical mitochondria in A-fibers of
mouse saphenous nerve. These atypical mitochondria
were always swollen and/or vacuolated (area > 0.20 μm2;
diameter > 500 nm). These criteria are very similar to
those used by authors who also found an increased in-
cidence of atypical axonal mitochondria in peripheral
nerves of rats with paclitaxel- [7,8], oxaliplatin- [32] or
bortezomib-induced neuropathy [33]. An increase in
swollen and/or vacuolated mitochondria has also been
reported in the peripheral nerves [34] and DRGs [35] of
Figure 4 Atypical axonal mitochondria in myelinated and
unmyelinated fibers of saphenous nerve of paclitaxel-treated
mice. High magnification of a swollen mitochondrion with
collapsed cristae at one pole, leaving a large vacuole (a). Swelling
and vacuolization, with loss of cristae and disorganized matrix, are
prominent in several mitochondria in myelinated (b) and unmyelinated
(c) fibers. Scale Bar: 1 μm.
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of patients with painful peripheral neuropathy induced
by 2’3’-dideoxycitidine (ddC) and HIV infection [36].
Hence, these mitochondrial structural alterations may be
a common characteristic of these types of neuropathy.
Our finding of a low incidence of atypical mitochon-
dria in naive mice appears to be a common observation
in normal animals fixed with aldehydes [7,35]. In the
present study, we processed all nerves using the same
methodology; the mitochondria conserved their double
membrane, their neighboring microtubules were well pre-
served, and the mitochondria from other cells (Schwann
cells, fibroblasts, endothelial cells) were normal. Conse-
quently, it is highly unlikely that the paclitaxel-induced in-
crease in atypical mitochondria was due to an unsuitable
fixation rather than to a neurotoxic effect of paclitaxel.
We also found an increase, although not statistically sig-
nificant, in atypical mitochondria in the saphenous nerves
of mice treated with paclitaxel-vehicle, similar to that re-
ported previously [8]. This is not surprising, given that
one of its main components, Cremophor EL, can directly
damage mitochondria [37].
It is known that paclitaxel-induced neuropathy is asso-
ciated with a hypersensitization of A-fibers without af-
fecting C-fibers in mice [4], and that paclitaxel mainly
impairs the functionality of large myelinated (A-β) fibers
in humans [1]. In agreement with these data, we found
that paclitaxel induced a significant increase in atypical
axonal mitochondria in A-fibers but not in C-fibers of
saphenous nerves from WT mice. The time-course of
the mitochondrial and behavioral alterations was similar,
and both were evident on day 10 and resolved by day 28.
An increase in axonal atypical mitochondria (also in par-
allel with the time-course of behavioral changes) was
previously reported in paclitaxel-treated rats [7,8]. In
these studies, however, both myelinated and unmyelin-
ated fibers were affected and the behavioral and mito-
chondrial changes peaked later (27 days) than in the
present study. The lack of significant effect of paclitaxel
in unmyelinated fiber mitochondria of WT mice in our
study could have been due to the greater percentage of
atypical mitochondria in unmyelinated than myelinated
fibers in control condition or to the greater variability in
such a percentage in unmyelinated fibers (which would
have affected the probability of reaching statistical sig-
nificant differences). However, we do not think that this
Figure 5 Effect of the genetic inactivation of the σ1R on paclitaxel-induced mitochondrial abnormalities. Effect of treatment with paclitaxel
or its vehicle on the percentage of atypical mitochondria on myelinated (a) and unmyelinated (b) fibers of saphenous nerves from WT and σ1R-KO
mice. Each point and vertical line represent the mean ± SEM of the percentage of atypical mitochondria relative to the total number of mitochondria
in each type of fiber at day PRE (before treatment) and at days 10 and 28 posttreatment (n = 3-5 animals per day). Statistically significant differences
between paclitaxel-treated WT mice and vehicle-treated WT mice and between the values on the pretreatment day and the days after treatment,
##p < 0.01; statistically significant differences between WT and σ1R-KO mice on the same day after treatment, *p < 0.05 (two-way ANOVA followed by
Bonferroni test).
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creases 7 times the percentage of atypical mitochondria
in A-fibers but only 1.5 times in C-fibers. Because the
percentage of atypical mitochondria in naive WT mice
C-fibers is around 10% it would have been perfectly pos-
sible to increase this value also 7 times without reaching
a plateau (since 90% of C-fibers mitochondria are typical
in naive animals and therefore are susceptible to become
atypical as a consequence of paclitaxel treatment) but, in
fact, we do not observed such effect. Instead, differences
between species may explain the discrepancy between
C-fiber mitochondrial alterations induced by paclitaxel
in rats [7,8] and in mice (present study), because import-
ant variations in the primary afferent unmyelinated
neurochemistry between mice and rats have been previ-
ously described [38,39]. In fact, when similar protocols
of paclitaxel treatment are used, the neuropathic pain in-
duced by paclitaxel peaked earlier and it is of shorter
duration in mice [5,29,40] than in rats [7,8]. Moreover, a
different involvement of spinal cord microglial activation
by paclitaxel in mice and rats has been reported [29,41,42].
Nevertheless, paclitaxel did not produce alterations
in the mitochondria of Schwann cells in rats [43] nor
in mice (present study). Although the details of the
paclitaxel-induced neuropathy seems not to be the same
in rats and mice, it is interesting to note that in both
species paclitaxel induces qualitatively similar behav-
ioral and mitochondrial changes, which suggest that
these are core characteristics of paclitaxel neuropathyindependently of the species considered. Therefore, our
results in mice and those previously reported by Bennett’s
group in rats suggest that paclitaxel-induced neuropathic
pain may result from an impairment of axonal mitochon-
dria. In fact, functional impairment of mitochondria was
recently reported in peripheral nerves from paclitaxel- and
oxaliplatin-treated rats [44].
Previous studies in mice [45-47] and rats [48-50] found
evidence of axonal degeneration or alterations in Schwann
cells or microtubules after paclitaxel administration. We
did not observed any of these structural irregularities,
probably because the single and cumulative doses used
here were markedly below those administered in the
above-mentioned studies (single dose, 2 mg/kg in the
present study vs. 5–50 mg/kg in the others; cumulative
dose, 10 vs. 20–280 mg/kg). This explanation is supported
by the absence of these structural anomalies in other stud-
ies using similarly low doses [7,43] to those tested in the
present study.
Genetic inactivation (σ1R-KO mice) or pharmacological
blockade (σ1R antagonist) of the σ1R prevented paclitaxel-
induced mitochondrial abnormalities and neuropathic pain
signs. This suggests that the σ1R must be present and play
a key functional role in the development of paclitaxel-
induced painful neuropathy and atypical mitochondria.
Therefore, the prophylactic effect of σ1R antagonists
such as BD-1063 (present work; [28]) and S1RA [28] on
the development of paclitaxel-induced cold and mech-
anical allodynia may be related to the prevention of
Figure 6 Transmission electron micrographs of myelinated and
unmyelinated fibers of the saphenous nerve 28 days after
paclitaxel treatment. Cross-section of myelinated and unmyelinated
fibers of WT mice (a), σ1R-KO mice (b) and BD-1063-treated WT mice
(c). Scale bar: 1 μm.
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the proposal of selective σ1R antagonists as a novel ap-
proach to the treatment of neuropathic pain [27].
It has been suggested that the mechanisms by which
paclitaxel cause the mitochondrial abnormalities may de-
rive from its binding to the β-tubulin associated with the
voltage-dependent anion channel (VDAC) [44]. VDAC is
the most abundant protein in the mitochondrial outer
membrane [51] and, under certain situations (e.g., mi-
tochondrial Ca2+ overload), may open the mitochondrial
permeability transition pore (mPTP) and eventually pro-
duce mitochondrial alterations, including mitochondrial
swelling and the release of accumulated Ca2+ [52]. Thus,
paclitaxel has been found to induce these effects in vitro
[53-55]. Another possible explanation of paclitaxel-in-
duced mitotoxicity is the indirect regulation of mPTP
through the binding of paclitaxel to bcl-2, reversing the
function of bcl-2 as a blocker of mPTP opening [56].
Taken together, these data suggest that paclitaxel may
induce mPTP opening by binding to the β-tubulin
joined to VDAC and/or to bcl-2, which would induce
mitochondrial swelling and increase the release of mito-
chondrial Ca2+ to the cytoplasm. The σ1R modulates
VDAC function [57] and tonically regulates the expres-
sion of bcl-2 proteins [58] and consequently may also
indirectly regulate mPTP opening, inhibiting mitochon-
drial swelling and Ca2+ release. Further studies are
warranted to test this hypothesis.
Conclusions
In summary, we found that the pharmacological block-
ade (σ1R antagonists) or genetic inactivation of σ1R
(knockout mice) prevents the sensory-nerve mitochon-
drial abnormalities induced by paclitaxel in parallel with
the prevention of neuropathic pain development. These
findings suggest that σ1R antagonists might have thera-




Experiments were performed in female WT (Charles
River, Barcelona, Spain) and female σ1R-KO (Laboratorios
Esteve, Barcelona, Spain) CD-1 mice weighing 25–30 g.
The σ1R-KO mice were generated on a CD-1 background
as previously described [23]. There are no gender differ-
ence in taxane-induced neuropathy [59], but since taxanes
are frequently used in treatment of breast and ovarian
Figure 7 Effect of the pharmacological blockade of the σ1R on paclitaxel-induced mitochondrial abnormalities. Effect of treatment with
paclitaxel + saline, paclitaxel-vehicle + saline, or paclitaxel + BD-1063 on the percentage of atypical mitochondria in myelinated (a) and unmyelinated
(b) fibers of saphenous nerves from WT mice. Each point and vertical line represent the mean ± SEM of the percentage of atypical mitochondria relative
to the total number of mitochondria in each type of fiber before treatment (PRE) and at days 10 and 28 posttreatment (n = 3-5 animals per
day). Statistically significant differences between WT mice treated with paclitaxel + saline and the rest of the groups on the same day after treatment,
**p < 0.01; and between the values on the pretreatment day and the days after treatment, ##p < 0.01 (two-way ANOVA followed by Bonferroni test).
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experiments in female mice. The animals were housed
in colony cages and kept in temperature- and light-
controlled rooms (22 ± 1ºC, lights on at 08.00 h and off at
20.00 h, air replacement every 20 min). Testing took place
during the light phase (from 9.00 h to 15.00 h). Mice were
handled in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/ECC).
The experimental protocol was approved by the University
of Granada Research Ethics Committee.
Drugs and drug administration
The drugs used were paclitaxel and the σ1 receptor antag-
onist BD-1063 (both from Tocris Cookson Ltd., Bristol,
United Kingdom). Paclitaxel was dissolved in a solution of
50% Cremophor EL and 50% absolute ethanol to obtain a
concentration of 6 mg/ml. This paclitaxel solution was di-
luted in sterile physiological saline to a final concentration
of 2 mg/10 ml just before its administration. For control
treatments, the paclitaxel-vehicle solution was also diluted
just before its administration in saline at the same propor-
tion as the paclitaxel solution. Paclitaxel (2 mg/kg) was ad-
ministered intraperitoneally (i.p.) in a volume of 10 ml/kg
once per day for 5 consecutive days (cumulative dose of
10 mg/kg); a schedule of paclitaxel treatment that pro-
duces a painful neuropathy in mice [5,28,29,40]. The con-
trol group was administered with the vehicle for paclitaxel
according to the same schedule.
BD-1063 (32 mg/kg) was dissolved in saline just before
the s.c. administration of a volume of 5 ml/kg in the
interscapular area. This dose of BD-1063 produces asignificant anti-allodynic effect in several models of pain
[23,28,62]. The control animals received s.c. the same
volume of saline. BD-1063 was s.c. administered to avoid
any possibility of chemical interaction with paclitaxel so-
lution (which was i.p. administered).
General procedures for drug treatments and behavioral
assays in pain models
The general procedures were performed as previously
described [5,28] with slight modifications. First, behav-
ioral responses were tested in each animal at 3 days be-
fore the start of paclitaxel administration (pretreatment
value). Then, animals were treated with drugs once daily
for 5 consecutive days. On each treatment day, animals
received an s.c. injection of saline or BD-1063 and then,
after a 30-min interval, an i.p. injection of paclitaxel or
its vehicle. Post-treatment responses were measured on
days 10 and 28 after the first paclitaxel or vehicle injec-
tion. These days were selected because the expression of
paclitaxel-induced cold and mechanical allodynia is
clearly established on day 10 [5,28] and there is no pain
behavior on day 28 (Figure 1a and b). Each animal was
tested alternately in both pain tests, with an interval of
24 h between evaluations, and was sacrificed after the
final measurement in order to obtain the saphenous
nerve, as described below. Only paclitaxel-treated WT
animals that showed both cold and mechanical allodynia
on day 10 were selected for the study of saphenous
nerve ultrastructure. The criteria for considering that an
animal had developed cold and mechanical allodynia
were those previously described [5]: for cold allodynia, if
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stimulated paws was higher or equal than 2 s; and for
mechanical allodynia if the mean of the threshold values
recorded on this day was lower (0.6 g or more) than the
mean of the animal’s pretreatment values (obtained
3 days before paclitaxel treatment was started).
The experimenter who evaluated the behavioral re-
sponses was blinded to the treatment and genotype of ex-
perimental subjects. In all cases, experiments in the σ1R-
KO or WT groups, vehicle- or paclitaxel-treated groups,
and saline- or BD-1063-treated groups were run in parallel.
Procedure to measure cold allodynia
Cold allodynia was tested by gently touching the plantar
skin of the hind paws with an acetone bubble using a
syringe connected to a thin tube as previously described
[5,28]. On each evaluation day, the mice were habituated
for 30 min in individual transparent boxes (7 × 7 × 13
cm) on an elevated platform with a wire mesh floor.
After the adaptation period, acetone was applied alter-
nately three times to each hind paw at intervals of 30 s,
and the duration of licking or biting was recorded with a
stopwatch and reported as the cumulative time of lick-
ing/biting at all six measurements. A cut-off time of 10 s
was used in each of the six trials.
Procedure to measure mechanical allodynia
Mechanical allodynia was assessed by measuring the
threshold force for hind paw withdrawal with an electronic
Voy Frey apparatus (Dynamic Plantar Aesthesiometer, Ugo
Basile, Comerio, Italy) as previously described [5,28]. This
electronic device uses a single nonflexible filament that ap-
plies increasing force (from 0 to 10 g) against the plantar
surface of the hind paw over a 20-s period. The nocifensive
paw withdrawal response automatically turns off the stimu-
lus, and the mechanical pressure that evokes the response
is recorded. On each day of the experiment, the mice were
habituated for 2 h in individual transparent boxes (9 × 9 ×
14 cm) with a wire mesh bottom and then tested three
times alternately in each hind paw, allowing at least 30 s
between each measurement. The mean of the six trial
values was considered the response of the animal.
Procedure to obtain saphenous nerves and electron
microscopy analysis
Mice were anesthetized with isofluorane (IsoVet®, B. Braun,
Barcelona, Spain) and perfused intracardially with 20 ml
saline followed by 30 ml of freshly prepared 2% glutaral-
dehyde/1% paraformaldehyde in 0.1 M phosphate buffer
(PB), pH 7.4, for 15 min. After perfusion, saphenous
nerves were dissected and processed as previously de-
scribed by Flatters and Bennett [7] with slight modifica-
tions. Briefly, 5 mm of saphenous nerves were dissected
at mid-thigh level and fixed with 2% glutaraldehyde/1%paraformaldehyde in 0.1 M PB, pH 7.4, overnight at
4°C. After fixation, samples were transferred to 10% su-
crose in 0.1 M PB for 24 h at 4°C and then postfixed
with 0.1% osmium tetroxide in 0.1 M PB, pH 7.4, con-
taining 1% potassium ferrocyanure for 1 h at 4ºC, dehy-
drated in a graded series of alcohols, and embedded in
Epoxy resin. Samples were sectioned with an Ultracut E
Reichert-Jung ultramicrotome (Leica, Barcelona, Spain)
to obtain ultrathin sections (70 nm) and then stained
with uranyl acetate and lead citrate.
Ultrathin sections were viewed in a Zeiss EM 902
(Zeiss, Oberckochem, Germany) transmission electron
microscope equipped with a monochrome CCD camera.
Micrographs were taken with the camera connected to a
video frame grabber (Snappy Video Snapshot, Play Inc.,
Rancho Cordova, CA) plugged into a PC (1500x1125
resolution). To perform ultrastructural and morphomet-
ric analyses, microphotographs were taken of myelinated
(n = 30) and unmyelinated (n = 30) axons of the saphe-
nous nerves from each mouse. ImageJ software (http://
rsb.info.nih.gov/ij/index.html) was used to measure the
area (A), perimeter (P), circularity (4π[A/P2]; 1.0 = perfect
circle), and Feret’s diameter (longest distance between any
two points along the selection boundary). Nerve fibers
were classified according to the presence or absence of the
myelin sheath as myelinated (A-fiber, n = 2100) or unmy-
elinated (C-fiber, n = 2100) fibers. Morphometric measure-
ments were conducted at 20000× for the area, perimeter,
circularity, and Feret’s diameter in mitochondria from
A- and C-fibers. Area values alone are given in the Results
section for the mitochondria, because the other mor-
phometric data were closely related to the area and were
similarly affected by treatments (data not shown). Morpho-
metric analyses were performed by observers who were
blind to the genotype or treatment group of the mice.
Analysis of mitochondria
Mitochondria from myelinated and unmyelinated fibers
were identified as circular or oval structures with a
double membrane containing cristae and amorphous
electron dense material that had an area of at least
0.02 μm2 (diameter > 165 nm). Analysis of mitochondrial
area (n = 10679) in the different fiber types in both WT
and σ1R-KO control mice allowed the observation of
mitochondrial populations of different sizes (see Results
section). Atypical mitochondria were observed in both
A- and C-fibers (see Results section) and defined on the
basis of a double membrane, vacuolization and/or pro-
nounced swelling, according to the criteria described by
Flatters and Bennett [7], slightly modified. Thus, pro-
nounced swelling was defined as an enlargement of
at least 2-fold the mean mitochondrial area of naive
mice. Given that the mitochondrial area was significantly
larger in the C-fibers than in the A-fibers of both WT
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swelling of a mitochondrion was considered when a mito-
chondrion had > 0.20 μm2 (diameter > 500 nm) in the
myelinated fibers and > 0.26 μm2 (diameter > 580 nm) in
the unmyelinated fibers. Vacuolated mitochondria are fre-
quently characterized by the accumulation of electron-
dense material in one of the poles of the mitochondria.
The incidence of atypical mitochondria was expressed as
the percentage of atypical mitochondria relative to the
total number of mitochondria measured.
Data analysis
Differences between values in the behavioral assays were
analyzed with two-way repeated measures analysis of
variance (ANOVA) followed by the Bonferroni test. Dif-
ferences between the frequencies of atypical mitochon-
dria were analyzed with two-way analysis of variance
(ANOVA) followed by the Bonferroni test. Differences
between the mean mitochondrial area were analyzed with
one-way and two-way analysis of variance (ANOVA)
followed by the Bonferroni test. SigmaPlot 12.0 (Systat
Software Inc., San Jose, CA) was used for all data analyses.
Differences between means were considered statistically
significant when the value of p was below 0.05.
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